Sage Journals: Discover world-class research

Abstract

Spanish

French

BACKGROUND:

Linezolid is an oxazolidinone antimicrobial with excellent oral bioavailability and tissue penetration and is active against multidrug-resistant skin/soft tissue pathogens.

OBJECTIVE:

To study the pharmacokinetics and antibacterial activity of linezolid against selective skin/soft tissue pathogens in obese patients.

METHODS:

We obtained multiple serum samples from 7 obese patients (>50% over their calculated ideal body weight) receiving oral linezolid 600 mg every 12 hours for treatment of cellulitis. Following a minimum of 3 doses, serum concentrations of linezolid were measured in each subject prior to (trough) and 1 and 6 hours after a dose. These samples were then tested against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) (linezolid minimum inhibitory concentrations [MICs] 1.0, 2.0, 4.0 μg/mL) and one strain each of vancomycin-resistant Enterococcus faecium (VRE) (MIC 2.0 μg/mL), Bacteroides fragilis (MIC 2.0 μg/mL), and Peptostreptococcus magnus (MIC 1.0 μg/mL). Serum inhibitory titers (SITs) and bactericidal titers (SBTs) were measured at each time point, and the median activity for these 7 patients was calculated.

RESULTS:

Mean linezolid serum concentrations were 4.2, 12.3, and 7.2 μg/mL at these respective time points. Median SITs for 12 hours (100% of the dosing interval) were observed against each organism with the exception of the least susceptible strain of MRSA (MIC 4.0 μg/mL); serum inhibitory activity was observed only at the one-hour time point against this isolate. Furthermore, prolonged (⩾6 h) median SBTs were observed against one isolate of MRSA (MIC 1.0 μg/mL) as well as the strain of VRE and P. magnus.

CONCLUSIONS:

Serum concentrations of oral linezolid in this patient population were diminished compared with those of healthy volunteers, but still provided prolonged serum inhibitory activity against common pathogens associated with skin/soft tissue infections. One treatment concern would be an obese patient receiving oral linezolid who was infected with a less susceptible (MIC ⩾4.0 μg/mL) strain of S. aureus. Bactericidal activity was also observed against selective pathogens.

Keywords

linezolid obesity pharmacodynamics pharmacokinetics

Get full access to this article

View all access options for this article.

References

Harbarth

Albrich

Goldman

Huebner

Control of multiply resistant cocci: Do international comparisons help?

Lancet Infect Dis 2001;1: 251–61.

Jones

Karlowsky

Draghi

Thornsberry

Sahn

Nathwani

Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: A guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003;22: 406–19.

Naimi

LeDell

Como-Sabetti

Borchardt

Boxrud

Etienne

Comparison of community-and healthcare-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290: 2976–84.

Said-Salim

Mathema

Kreiswirth

. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging pathogen. Infect Control Hosp Epidemiol 2003;24: 451–5.

Eliopoulos

. Quinupristin-dalfopristin and linezolid: Evidence and opinion. Clin Infect Dis 2003;36: 473–81.

Richter

Kealey

Murray

Heilmann

Coffman

Doern

. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2003;52: 123–7.

Stalker

Jingbluth

Hopkins

Batts

. Pharmacokinetics and tolerance of single-and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51: 1239–46.

Kutscha-Lissberg

Hebler

Muhr

Koller

Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003;47: 3964–6.

Lovering

Zhang

Bannister

Lankester

BJA

Brown

JHM

Narendra

Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002;50: 73–7.

10.

MacGowan

. Pharmacokinetic and pharmacodynamic profiles of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 2003;51(suppl 2):17–25.

11.

Baddour

. Recent considerations in recurrent cellulitis. Curr Infect Dis Rep 2001;3: 461–5.

12.

Stein

Schooley

Kak

Havlichek

. Oral linezolid as alternative therapy in patients with cellulitis who have been referred to an infusion center. Pharm Ther 2004;29: 510–1.

13.

Wurtz

Itokazu

Rodvold

Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25: 112–8.

14.

Shaikh

ZHA

Peloquin

Ericsson

. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: Case report and literature review. Scand J Infect Dis 2001;33: 375–9.

15.

Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved standard. Document no. M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards. 2000;20: 10–4.

16.

Methods for antimicrobial susceptibility testing of anaerobic bacteria. 5th ed. Approved standard. Document no. M11-A5. Wayne, PA: National Committee for Clinical Laboratory Standards. 2001.

17.

Methods for determining bactericidal activity of antimicrobial agents. Approved guideline. Document no. M26-A. Villanova, PA: National Committee for Clinical Laboratory Standards. 1999;19.

18.

Livermore

. Linezolid in vitro: Mechanism and antibacterial spectrum. J Antimicrob Chemother 2003;51(suppl 2):9–16.

19.

Moellering

. Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med 2003;138: 135–42.

20.

Lipsky

Itani

Norden

Treating foot infections in diabetic patients: A randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004;38: 17–24.

21.

Stevens

Smith

Bruss

McConnell-Martin

Duvall

Todd

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44: 3408–13.

22.

Burkhardt

Barner

vonder Hoh

Koppe

Pletz

Nord

Single-and multiple-dose pharmacokinetics of linezolid and coamoxiclav in healthy human volunteers. J Antimicrob Chemother 2002;50: 707–12.

23.

Meagher

Forrest

Rayner

Birmingham

Schentag

. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003;47: 548–53.

24.

Moellering

. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999;130: 155–7.

25.

Cha

Akins

Rybak

. Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacokinetic model. Pharmacotherapy 2003;23: 1531–7.

26.

Cha

Brown

Rybak

. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2003;47: 3960–3.

27.

Yagi

Zurenko

. An in vitro time-kill assessment of linezolid and anaerobic bacteria. Anaerobe 2003;9: 1–3.

28.

Leggett

Craig

. Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli. Antimicrob Agents Chemother 1989;33: 35–40.

29.

Andes

van Ogtrop

Peng

Craig

. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46: 3484–9.

30.

Rayner

Forrest

Meagher

Birmingham

Schentag

. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use program. Clin Pharmacokinet 2003;42: 1411–23.

31.

Bosso

Flume

Gray

. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2004;48: 281–4.

32.

Schaadt

Batts

Daley-Yates

Pawsey

Stalker

Zurenko

. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones aperezolid and linezolid. Diagn Microbiol Infect Dis 1997;28: 201–4.

33.

Pankey

Sabath

. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004;38: 864–70.

34.

Birmingham

Rayner

Meagher

Flavin

Batts

Schentag

. Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate use program. Clin Infect Dis 2003;36: 159–68.

35.

Babcock

Ritchie

Christiansen

Starlin

Little

Stanley

Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32: 1373–5.

36.

Till

Wixson

Pertel

. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;34: 1412–4.

37.

Rayner

Baddour

Birmingham

Norden

Meagher

Schentag

. Linezolid in the treatment of osteomyelitis: Results of compassionate use experience. Infection 2004;32: 8–14.

Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis

Abstract

BACKGROUND:

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSIONS:

Keywords

Get full access to this article

References